Skip to product information
Noopept 10mgx90 - RCpeptides
Noopept 1gr

Noopept 1gr

€20,00 EUR
Taxes included.

                                       NOT FOR HUMAN CONSUMPTION

Noopept is a small dipeptidomimetic nootropic developed in Russia. After oral dosing it is rapidly hydrolyzed to cyclo-L-prolylglycine (cPG) and related fragments that modulate glutamatergic signaling, enhance neurotrophin expression (BDNF/NGF), and exert antioxidant/anti-inflammatory effects. In clinical practice (primarily Eastern Europe), it has been used for mild cognitive impairment (MCI) and post-injury cognitive symptoms. It is not FDA/EMA-approved; evidence outside Russia is limited and heterogeneous.

Additional Benefits of Noopept Now Under Investigation

Benefit Key take-aways
1 Cognitive performance in MCI Small randomized and open-label trials report improved memory, attention, and global cognitionvs baseline and piracetam-class comparators over 1–3 months. <br/><em>Neuroscience & Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii</em>
2 Anxiolytic and anti-asthenic effects Reductions in trait anxiety, emotional lability, and fatigue have been observed alongside cognitive gains, with good daytime tolerability. <br/><em>CNS Drugs; Human Psychopharmacology</em>
3 Post-TBI/stroke cognitive recovery Animal models and small clinical series show better learning, faster processing, and improved daily function during rehabilitation. <br/><em>Brain Research; Stroke & Vascular Neurology</em>
4 Neurotrophic up-regulation Hippocampal BDNF and NGF mRNA/protein increase after Noopept/cPG, supporting synaptic plasticity. <br/><em>Molecular Neurobiology; Journal of Neurochemistry</em>
5 Anti-amyloid & synaptoprotection Attenuates Aβ-induced toxicity, normalizes synaptic markers, and improves task performance in AD-like models. <br/><em>Journal of Alzheimer’s Disease; Neurobiology of Aging</em>
6 Antioxidant/anti-inflammatory actions Lowers lipid peroxidation (MDA), restores glutathione/SOD, and down-shifts NF-κB/TNF-α/IL-1β, contributing to neuroprotection. <br/><em>Free Radical Biology & Medicine; Journal of Neuroinflammation</em>
7 Visual and sensory processing Normalization of evoked-potential latencies and contrast sensitivity reported in MCI/vascular cognitive impairment subgroups. <br/><em>Clinical Neurophysiology; Vision Research</em>
8 Sleep/circadian symptoms Exploratory data suggest reduced daytime sleepiness without stimulant-type disruption of sleep architecture. <br/><em>Sleep Medicine; Psychopharmacology</em>
9 Safety in older adults Short-course use (10–30 mg/day) generally well tolerated with low discontinuation; comparative safety vs racetams favorable in small programs. <br/><em>Drugs & Aging; International Journal of Geriatric Psychiatry</em>

2. Molecular Mechanism of Action

2.1 Pharmacodynamics

  • Prodrug → cPG: Oral Noopept yields cyclo-L-prolylglycine, which modulates AMPA/NMDA tone and Ca²⁺ homeostasis, improving LTP/LTD balance.

  • Neurotrophins: Up-regulates BDNF/NGF and Trk-dependent pathways (CREB/MAPK), supporting dendritic spine maintenance and synaptogenesis.

  • Redox/Inflammation: Enhances antioxidant enzymes, reduces ROS/NO overproduction, and modulates NF-κB.

  • Anti-excitotoxicity: Limits glutamate-driven damage and stabilizes mitochondrial membrane potential in stressed neurons.

2.2 Down-stream Biology

Pathway Functional outcome Context
cPG → AMPA/NMDA tuning; CREB ↑ LTP, memory consolidation Hippocampus/cortex
BDNF/NGF → Trk/ERK/PI3K ↑ Synaptic plasticity, neurogenesis Learning circuits
Antioxidant (SOD/GSH) & Nrf2 ↓ ROS/lipid peroxidation, mitochondrial protection Oxidative stress
NF-κB/TNF-α/IL-1β down-shift ↓ Neuroinflammation Injury/degeneration
Aβ toxicity mitigation Preserves synapses, behavior AD-like models

3. Pharmacokinetics

  • Absorption/BBB: Rapid oral absorption; brain-penetrant small peptide ester.

  • Onset/Duration: Subjective effects within days; steady neurotrophic changes accrue over weeks.

  • Half-life: Short (hours) for parent; active fragments may persist longer in CNS.

  • Dosing in studies: 10–30 mg/day in 1–3 divided doses for 1–3 months, sometimes cyclic.

  • Elimination: Hydrolysis to amino-acid derivatives; renal/hepatic peptide catabolism.

4. Pre-clinical and Translational Evidence

4.1 Cognitive impairment (vascular/MCI)

Small RCTs and open-label trials (primarily Russia/Eastern Europe) show improved memory/attention and global scales vs baseline and vs piracetam, with favorable tolerability.

4.2 Neuroprotection (ischemia/TBI)

Rodent models demonstrate reduced neuronal death, better spatial learning, and motor recovery when given peri-injury.

4.3 Alzheimer-like pathology

In Aβ-infusion/APP models, Noopept reduces amyloid toxicity, normalizes synaptic proteins, and improves behavioral tasks.

Evidence quality note: Human data are limited, regional, and heterogeneous; many studies are small and short. Larger multicenter, placebo-controlled trials using harmonized endpoints are needed.

5. Emerging Clinical Interests

Field Rationale Current status
Post-concussive/long-COVID “brain fog” Anti-inflammatory + neurotrophic signaling Pilot/exploratory
Vascular cognitive impairment Antioxidant/vasculoneuronal support Small RCTs; replication needed
Chemo-related cognitive impairment Synaptic rescue, redox balance Preclinical → feasibility
Age-related cognitive decline BDNF/NGF up-shift with good tolerability Early clinical signals
Anxiety with cognitive symptoms Anxiolytic + procognitive in dysexecutive states Small trials/series

6. Safety and Tolerability

  • Common: Headache, irritability, mild insomnia or somnolence, nausea/dyspepsia—usually transient and dose-related.

  • Less common: BP sensitivity, allergic rash, restlessness in stimulant-sensitive users.

  • Drug interactions (theoretical/observed): Additive CNS effects with stimulants, racetams, or high-dose caffeine; consider spacing with sedative-hypnotics.

  • Special populations: Insufficient data in pregnancy, breastfeeding, severe hepatic/renal disease—avoid outside trials.

  • Abuse potential: Low (non-euphoric).

  • Discontinuation: Generally uncomplicated; no withdrawal syndrome reported.

Comparative safety matrix

Concern Noopept Piracetam Aniracetam Modafinil
Mechanism cPG → glutamate tuning; neurotrophins AMPA/NMDA modulation (weak) AMPA-positive modulator Wake-promoter (DAT/orexin)
Evidence in MCI Small RCTs (regional) Extensive legacy (mixed) Small studies (mixed) Not indicated
Anxiolysis Yes (signals) Neutral Often yes Variable; can be activating
Headache/insomnia Mild Mild Mild Insomnia common
Regulatory status Approved regionally (RU) Varies by country Supplement/drug (varies) Approved (narcolepsy, etc.)

7. Regulatory Landscape

  • Russia/Eastern Europe: Marketed prescription nootropic for cognitive impairment.

  • US/EU/UK/CA: Not approved as a medicine; appears on research-chemical/“nootropic” markets—quality varies and clinical claims are unregulated.

8. Future Directions

  • Multicenter RCTs in MCI/VCI with validated composites (e.g., ADAS-Cog, CDR-SB, SAGE) and digital cognitive endpoints.

  • Biomarkers: CSF/plasma BDNF/NGF, inflammatory panels, EEG/ERP and fMRI connectivity readouts.

  • Head-to-head vs piracetam-class agents and vs standard cognitive rehab.

  • Formulation science: Controlled-release or intranasal routes to optimize CNS exposure and reduce GI effects.

  • Combination strategies: Pair with aerobic/resistance exercise or multidomain lifestyle programs to potentiate neuroplasticity.

Selected References

  • Neuroscience & Behavioral Physiology; Zhurnal Nevrologii i Psikhiatrii — Clinical studies of Noopept in MCI/vascular cognitive impairment.

  • CNS Drugs; Human Psychopharmacology — Anxiolytic and procognitive profiles of peptide nootropics.

  • Molecular Neurobiology; Journal of Neurochemistry — BDNF/NGF signaling and synaptic plasticity under Noopept/cPG.

  • Journal of Alzheimer’s Disease; Neurobiology of Aging — Anti-amyloid and synaptoprotective effects.

  • Brain Research; Stroke & Vascular Neurology — Neuroprotection after TBI/ischemia.

  • Free Radical Biology & Medicine; Journal of Neuroinflammation — Antioxidant and anti-inflammatory mechanisms.

  • Clinical Neurophysiology; Vision Research — Evoked-potential and sensory-processing findings.

  • Drugs & Aging; International Journal of Geriatric Psychiatry — Tolerability in older adults and comparative context.